E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction A TIMI 14 Substudy
C. Michael Gibson,James A. de Lemos,Sabina A. Murphy,Susan J. Marble,Carolyn H. McCabe,Christopher P. Cannon,Elliott M. Antman,Eugene Braunwald +7 more
TL;DR: Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI, providing a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMi.
Journal Article
Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials.
TL;DR: All three classes of agents reduced the ventricular rate in patients who developed the arrhythmia, although the ventocard rate reduction was not clinically optimal, and had a protective effect against the development of SVAs in a select population of patients undergoing CABG.
Journal ArticleDOI
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Iván Horváth,Matyas Keltai,Jean Paul R. Herrman,Frans Van de Werf,William E. Downey,Benjamin M. Scirica,Sabina A. Murphy,Elliott M. Antman +10 more
TL;DR: Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel, and the data affirm the importance of intensive platelet inhibition in patients with intracoronary stents.
Journal ArticleDOI
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
Sidney C. Smith,Ted Feldman,John W. Hirshfeld,Alice K. Jacobs,Morton J. Kern,Spencer B. King,Douglass A. Morrison,William W. O'Neill,Hartzell V. Schaff,Patrick L. Whitlow,David O. Williams,Elliott M. Antman,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Jonathan L. Halperin,Loren F. Hiratzka,Sharon A. Hunt,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +22 more
Journal ArticleDOI
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
TL;DR: The rate of major spontaneous hemorrhage for both heparin and hirudin in TIMi 9A was higher than that seen in TIMI 5, TIMI 6, and GUSTO 1 and it now appears important to monitor aPTT on a regular basis when using either antithrombin to identify those patients who require downward adjustment of the infusion.